Alzheimer's disease: which type of amyloid-preventing drug agents to employ? - Wikidata - wikimedia - TriplyDB

Alzheimer's disease: which type of amyloid-preventing drug agents to employ?

Alzheimer's disease: which type of amyloid-preventing drug agents to employ?

http://www.wikidata.org/entity/Q34330351

about

Deciphering the glycolipid code of Alzheimer's and Parkinson's amyloid proteins allowed the creation of a universal ganglioside-binding peptide Familial Alzheimer's disease Osaka mutant (ΔE22) β-barrels suggest an explanation for the different Aβ1-40/42 preferred conformational states observed by experiment.Activity and architecture of pyroglutamate-modified amyloid-β (AβpE3-42) pores Differences between amyloid-β aggregation in solution and on the membrane: insights into elucidation of the mechanistic details of Alzheimer's disease.Disordered amyloidogenic peptides may insert into the membrane and assemble into common cyclic structural motifs.Nanomaterials enhanced surface plasmon resonance for biological and chemical sensing applications.Role of the fast kinetics of pyroglutamate-modified amyloid-β oligomers in membrane binding and membrane permeability.Amyloid β oligomers in Alzheimer's disease pathogenesis, treatment, and diagnosis.Amyloid-β peptides in interaction with raft-mime model membranes: a neutron reflectivity insight.Bexarotene blocks calcium-permeable ion channels formed by neurotoxic Alzheimer's β-amyloid peptides.Membrane-Accelerated Amyloid-β Aggregation and Formation of Cross-β Sheets.Common molecular mechanism of amyloid pore formation by Alzheimer's β-amyloid peptide and α-synuclein.Small molecule NPT-440-1 inhibits ionic flux through Aβ1-42 pores: Implications for Alzheimer's disease therapeutics.Anthoxanthin Polyphenols Attenuate Aβ Oligomer-induced Neuronal Responses Associated with Alzheimer's Disease.

P2860

Q28542419-B325E940-469E-484E-A134-A1F47076F3CF Q30153519-ECD31297-8C27-4299-BBFA-CDB85FDCC576 Q33894606-3240BE3A-377B-4965-A1A7-6F50769F94F0 Q33946695-EC1E548F-6D47-4E77-BCE9-E66465C1C7C2 Q34084687-F75F078A-D287-43F0-B9BA-412B3C638E22 Q34405112-61087F66-03E4-45FD-A38C-89AFCDEFC313 Q34434154-87F8B396-6A60-41DD-8CFC-CAB448B2C7E5 Q35327172-5046BF07-0DF6-42EE-BD69-09C5AC1DF5D4 Q38477716-C571CE87-3F16-41F7-8C69-4FE4307DDECC Q39037884-5C4F3B3F-DFF6-4463-A3B3-EAC831840A1D Q41666582-92FCCCA9-90D7-4D83-A7FC-D575963E5BEC Q42517974-EE7B38E2-EE06-43E2-AC7F-2829E0CCBB7B Q42756593-E92BC03C-A87D-4891-AF82-B47C3DE2EDE8 Q46457366-32B77D42-4845-4AFA-A4E9-F6BA1F9FA628

P2860

Alzheimer's disease: which type of amyloid-preventing drug agents to employ?

http://www.wikidata.org/entity/Q34330351

description

2013 nî lūn-bûn

@nan

2013 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

Alzheimer's disease: which type of amyloid-preventing drug agents to employ?

@ast

Alzheimer's disease: which type of amyloid-preventing drug agents to employ?

@en

Alzheimer's disease: which type of amyloid-preventing drug agents to employ?

@nl

type

label

Alzheimer's disease: which type of amyloid-preventing drug agents to employ?

@ast

Alzheimer's disease: which type of amyloid-preventing drug agents to employ?

@en

Alzheimer's disease: which type of amyloid-preventing drug agents to employ?

@nl

prefLabel

Alzheimer's disease: which type of amyloid-preventing drug agents to employ?

@ast

Alzheimer's disease: which type of amyloid-preventing drug agents to employ?

@en

Alzheimer's disease: which type of amyloid-preventing drug agents to employ?

@nl

P1433

Q34330351-843AD03C-A96C-4DC5-83AB-BC30C21FA496

P1476

Q34330351-99F9C565-88D1-46AE-B3D6-D4876867DDA1

P2093

Q34330351-A7EABD14-188F-4A4C-B553-91F1D8D28500

Q34330351-AEE7BB74-CFD1-4A5A-AB54-10605A7DA928

Q34330351-BAFE9311-58FA-43B8-B22B-8273CDD9B03A

Q34330351-C902843D-F335-418F-A646-1605BBD5C80A

P2860

Q34330351-01306BDD-BD77-4CBD-A40D-57DB1143326B

Q34330351-028A140A-2474-4243-802A-F0E781CAA3F7

Q34330351-05AD7B08-30FA-4787-8ADB-870B1ECD0097

Q34330351-0748622A-AF77-4278-A719-FD67A310AE01

Q34330351-086D66EA-2B79-4EE3-9E25-9E905A3D6C54

Q34330351-0AC45616-FC4D-4ED6-9222-F5A15E8F9B1E

Q34330351-0C90942C-8944-4B86-A6EF-8E9747D87969

Q34330351-0F74027A-7239-4D48-B7CA-BE2DE013CA1A

Q34330351-1087408D-5E08-423E-85D5-0CB85BDAC8A8

Q34330351-159903DE-4E88-44A7-887A-5BA295DDE480

P304

Q34330351-CBAC5F61-2015-4F4C-9261-A9DC93AFF9B7

P31

Q34330351-28E8810E-5195-4269-9EB7-73BE80627A1E

P356

Q34330351-9FB30F27-AD22-472D-B877-6E0AB4DC7781

P407

Q34330351-40AD40E5-9A9C-499F-99BB-7F0D3BFDE0E3

P433

Q34330351-414CE29A-F442-4BD8-B063-02EC0BC64D7F

P478

Q34330351-126D834E-CE55-4C81-B65B-A51892C1C01A

P50

Q34330351-4A555DEB-2F66-4666-A83D-24120CAA3847

Q34330351-95DE2989-2418-4DAA-846D-11DB22B8514F

Q34330351-CED22013-2EC8-40E0-85A3-29A725BCCFAD

P577

Q34330351-5A92EED9-4280-404B-8A10-6EF527474C79

P698

Q34330351-81E824BD-D9D1-4F60-B4C4-577983DC08B9

P921

Q34330351-19907795-441E-4668-ADB3-2F53E1C56DD0

P932

Q34330351-6F97BAFD-9E94-4083-925C-9CACDB71049A

P356

P1433

Physical Chemistry Chemical Physics

P1476

Alzheimer's disease: which type of amyloid-preventing drug agents to employ?

@en

P2093

Bruce L Kagan

http://www.w3.org/2001/XMLSchema#string

Hyunbum Jang

http://www.w3.org/2001/XMLSchema#string

Laura Connelly

http://www.w3.org/2001/XMLSchema#string

Ratnesh Lal

http://www.w3.org/2001/XMLSchema#string

P2860

A Oligomer-Induced Aberrations in Synapse Composition, Shape, and Density Provide a Molecular Basis for Loss of Connectivity in Alzheimer's Disease

New Class of Inhibitors of Amyloid-beta Fibril Formation. IMPLICATIONS FOR THE MECHANISM OF PATHOGENESIS IN ALZHEIMER'S DISEASE

Apolipoprotein E, Dementia, and Cortical Deposition of β-Amyloid Protein

A partially folded structure of amyloid-beta(1-40) in an aqueous environment

Solution structure of the Alzheimer amyloid beta-peptide (1-42) in an apolar microenvironment. Similarity with a virus fusion domain

Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo

Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization

Alzheimer disease amyloid beta protein forms calcium channels in bilayer membranes: blockade by tromethamine and aluminum

The alpha-to-beta conformational transition of Alzheimer's Abeta-(1-42) peptide in aqueous media is reversible: a step by step conformational analysis suggests the location of beta conformation seeding

Experimental constraints on quaternary structure in Alzheimer's beta-amyloid fibrils

P304

8868-8877

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1039/C3CP00017F

http://www.w3.org/2001/XMLSchema#string

P407

P433

23

http://www.w3.org/2001/XMLSchema#string

P478

15

http://www.w3.org/2001/XMLSchema#string

P50

Srinivasan Ramachandran

Fernando Teran Arce

P577

2013-02-28T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23450150

http://www.w3.org/2001/XMLSchema#string

P921

Alzheimer's disease

P932

3663909

http://www.w3.org/2001/XMLSchema#string